638 related articles for article (PubMed ID: 24555235)
1. [Treatment possibilities in advanced Parkinson's disease].
Takáts A; Nagy H; Radics P; Tóth A; Tamás G
Ideggyogy Sz; 2013 Nov; 66(11-12):365-71. PubMed ID: 24555235
[TBL] [Abstract][Full Text] [Related]
2. Duodenal levodopa infusion monotherapy vs oral polypharmacy in advanced Parkinson disease.
Nyholm D; Nilsson Remahl AI; Dizdar N; Constantinescu R; Holmberg B; Jansson R; Aquilonius SM; Askmark H
Neurology; 2005 Jan; 64(2):216-23. PubMed ID: 15668416
[TBL] [Abstract][Full Text] [Related]
3. [Experience with levodopa/carbidopa intestinal gel in the treatment of advanced Parkinson's disease in Hungary].
Nagy H; Takáts A; Tóth A; Bereczki D; Klivényi P; Dézsi L; Dibó G; Vécsei L; Kovács N; Aschermann Z; Komoly S; Varannai L; Zemlényi G; Valikovics A
Ideggyogy Sz; 2014 Nov; 67(11-12):385-9. PubMed ID: 25720240
[TBL] [Abstract][Full Text] [Related]
4. [Application of levodopa/carbidopa intestinal gel in advanced Parkinson's disease].
Toth A; Nagy H; Wacha J; Bereczki D; Takáts A
Neuropsychopharmacol Hung; 2015 Dec; 17(4):191-6. PubMed ID: 26727723
[TBL] [Abstract][Full Text] [Related]
5. [Prevention and treatment of fluctuations in patients with Parkinson's disease].
Ludin HP; Surber Ch
Praxis (Bern 1994); 2006 Dec; 95(51-52):2013-8. PubMed ID: 17294589
[TBL] [Abstract][Full Text] [Related]
6. [Continuous dopaminergic stimulation by Duodopa in advanced Parkinson's disease: Efficacy and safety].
Annic A; Devos D; Seguy D; Dujardin K; Destée A; Defebvre L
Rev Neurol (Paris); 2009; 165(8-9):718-27. PubMed ID: 19150100
[TBL] [Abstract][Full Text] [Related]
7. Advanced Parkinson's disease: clinical characteristics and treatment. Part II.
Kulisevsky J; Luquin MR; Arbelo JM; Burguera JA; Carrillo F; Castro A; Chacón J; García-Ruiz PJ; Lezcano E; Mir P; Martinez-Castrillo JC; Martínez-Torres I; Puente V; Sesar A; Valldeoriola-Serra F; Yañez R
Neurologia; 2013; 28(9):558-83. PubMed ID: 23880230
[TBL] [Abstract][Full Text] [Related]
8. Sleep improvement with levodopa/carbidopa intestinal gel infusion in Parkinson disease.
Zibetti M; Rizzone M; Merola A; Angrisano S; Rizzi L; Montanaro E; Cicolin A; Lopiano L
Acta Neurol Scand; 2013 May; 127(5):e28-32. PubMed ID: 23311399
[TBL] [Abstract][Full Text] [Related]
9. [Current possibilities of quality of life improvement in the late stages of Parkinson's disease].
Titova NV; Katunina EA
Zh Nevrol Psikhiatr Im S S Korsakova; 2015; 115(3):94-100. PubMed ID: 26171484
[TBL] [Abstract][Full Text] [Related]
10. Quality of life in early Parkinson's disease treated with levodopa/carbidopa/entacapone.
Fung VS; Herawati L; Wan Y; ;
Mov Disord; 2009 Jan; 24(1):25-31. PubMed ID: 18846551
[TBL] [Abstract][Full Text] [Related]
11. [Current treatment strategies for Parkinson's disease].
Südmeyer M; Wojtecki L; Schnitzler A
Fortschr Neurol Psychiatr; 2011 Dec; 79(12):733-43. PubMed ID: 22161168
[No Abstract] [Full Text] [Related]
12. Medical treatment of Parkinson's disease.
Ahlskog JE
Compr Ther; 1989 Mar; 15(3):53-9. PubMed ID: 2650977
[No Abstract] [Full Text] [Related]
13. When the going gets tough: how to select patients with Parkinson's disease for advanced therapies.
Worth PF
Pract Neurol; 2013 Jun; 13(3):140-52. PubMed ID: 23487815
[TBL] [Abstract][Full Text] [Related]
14. [Selection of the optimal device-aided therapy in Parkinson's disease].
Kovács N; Aschermann Z; Juhász A; Harmat M; Pintér D; Janszky J
Ideggyogy Sz; 2019 Jan; 72(1-2):5-11. PubMed ID: 30785241
[TBL] [Abstract][Full Text] [Related]
15. [Clinical studies with levodopa/carbidopa intestinal gel].
Klivényi P; Vécsei L
Ideggyogy Sz; 2014 Jan; 67(1-2):5-8. PubMed ID: 24654442
[TBL] [Abstract][Full Text] [Related]
16. Duodenal Levodopa Infusion for Long-Term Deep Brain Stimulation-Refractory Symptoms in Advanced Parkinson Disease.
Regidor I; Benita V; Del Álamo de Pedro M; Ley L; Martinez Castrillo JC
Clin Neuropharmacol; 2017; 40(3):103-107. PubMed ID: 28452905
[TBL] [Abstract][Full Text] [Related]
17. What to do when Sinemet fails: Part one.
Klawans HL
Clin Neuropharmacol; 1984; 7(2):121-33. PubMed ID: 6733692
[No Abstract] [Full Text] [Related]
18. Cost-utility analysis of levodopa carbidopa intestinal gel (Duodopa) in the treatment of advanced Parkinson's disease in patients in Scotland and Wales.
Kalabina S; Belsey J; Pivonka D; Mohamed B; Thomas C; Paterson B
J Med Econ; 2019 Mar; 22(3):215-225. PubMed ID: 30484353
[TBL] [Abstract][Full Text] [Related]
19. Effect of levodopa-carbidopa intestinal gel on dyskinesia in advanced Parkinson's disease patients.
Antonini A; Fung VS; Boyd JT; Slevin JT; Hall C; Chatamra K; Eaton S; Benesh JA
Mov Disord; 2016 Apr; 31(4):530-7. PubMed ID: 26817533
[TBL] [Abstract][Full Text] [Related]
20. Use of advanced therapies for Parkinson's disease in Norway.
Ezat B; Pihlstrøm L; Aasly J; Tysnes OB; Egge A; Dietrichs E
Tidsskr Nor Laegeforen; 2017 May; 137(9):619-623. PubMed ID: 28468476
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]